Skip to content
Home/Companies/Biotech/Gamamabs

Gamamabs

Biotech·France·Active·11yr hold
Entry
2015
Hold
11yr
Status
Active

Who owns Gamamabs?

Gamamabs is a French Biotech company, currently owned by Andera Partners since 2015.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Andera Partners
Investor
Andera Partners
BioDiscovery 4 · 2013 · VC

Key facts

HQFrance
SectorBiotech

More from BioDiscovery 4

Other portfolio companies in the same fund.

Inotrem
Active
BiotechFrance
MedDay Pharmaceuticals
Exited 2021
BiotechFrance· 2016
Verona Pharma
Verona Pharma
Exited 2017
BiotechUK· 2016
Autonomic Technologies
Exited 2020
MedTechUS· 2015
to Unity HA
ReViral
Exited 2022
BiotechUK· 2015
to Pfizer
Sanifit
Exited 2021
BiotechSpain· 2015
to Vifor Pharma

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Gamamabs?

Gamamabs is currently owned by Andera Partners, through BioDiscovery 4, since 2015.

When did Andera Partners acquire Gamamabs?

Andera Partners acquired Gamamabs in 2015.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue